Which has higher earnings & valuation, IMNM or ALT?

Altimmune has lower revenue, but higher earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunome $6.94M 296.34 -$212.39M -$2.38 N/A Altimmune $40K 12,689.17 -$88.09M -$0.93 N/A

Is IMNM or ALT more profitable?

Immunome has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% Altimmune -214,860.98% -42.57% -35.57%

Does the media favor IMNM or ALT?

In the previous week, Immunome had 1 more articles in the media than Altimmune. MarketBeat recorded 7 mentions for Immunome and 6 mentions for Altimmune. Immunome's average media sentiment score of 0.93 beat Altimmune's score of 0.56 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AUPH or ALT?

In the previous week, Aurinia Pharmaceuticals had 3 more articles in the media than Altimmune. MarketBeat recorded 9 mentions for Aurinia Pharmaceuticals and 6 mentions for Altimmune. Aurinia Pharmaceuticals' average media sentiment score of 0.95 beat Altimmune's score of 0.56 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ALT or PHVS?

Altimmune has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Altimmune $40K 12,689.17 -$88.09M -$0.93 N/A Pharvaris N/A N/A -$198.79M -$3.18 N/A

Is ALT or PHVS more profitable?

Pharvaris has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Altimmune -214,860.98% -42.57% -35.57% Pharvaris N/A -67.56% -61.13%

Does the media prefer ALT or PHVS?

In the previous week, Altimmune had 2 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for Altimmune and 4 mentions for Pharvaris. Altimmune's average media sentiment score of 0.56 beat Pharvaris' score of 0.43 indicating that Altimmune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALT or BHC more profitable?

Bausch Health Cos has a net margin of -11.47% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Bausch Health Cos' return on equity. Company Net Margins Return on Equity Return on Assets Altimmune -214,860.98% -42.57% -35.57% Bausch Health Cos -11.47% -2,922.77% 5.63%

Does the media prefer ALT or BHC?

In the previous week, Altimmune had 5 more articles in the media than Bausch Health Cos. MarketBeat recorded 6 mentions for Altimmune and 1 mentions for Bausch Health Cos. Altimmune's average media sentiment score of 0.56 beat Bausch Health Cos' score of 0.49 indicating that Altimmune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ALT or MLYS?

In the previous week, Altimmune had 1 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 6 mentions for Altimmune and 5 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.59 beat Altimmune's score of 0.56 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Altimmune (ALT) Competitors

$2.61 -0.05 (-1.88%)

Closing price 04:00 PM Eastern

Extended Trading

$2.63 +0.02 (+0.80%)

As of 07:47 PM Eastern

Compare

ALT vs. IMNM, AUPH, PHVS, BHC, and MLYS

Should you buy Altimmune stock or one of its competitors? MarketBeat compares Altimmune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Altimmune include Immunome (IMNM), Aurinia Pharmaceuticals (AUPH), Pharvaris (PHVS), Bausch Health Cos (BHC), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry.

How does Altimmune compare to Immunome?

Immunome (NASDAQ:IMNM) and Altimmune (NASDAQ:ALT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Immunome has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Altimmune	-214,860.98%	-42.57%	-35.57%

Altimmune has lower revenue, but higher earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	296.34	-$212.39M	-$2.38	N/A
Altimmune	$40K	12,689.17	-$88.09M	-$0.93	N/A

44.6% of Immunome shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 7.2% of Immunome shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Immunome currently has a consensus price target of $33.17, suggesting a potential upside of 82.64%. Altimmune has a consensus price target of $16.67, suggesting a potential upside of 538.57%. Given Altimmune's higher possible upside, analysts clearly believe Altimmune is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Immunome had 1 more articles in the media than Altimmune. MarketBeat recorded 7 mentions for Immunome and 6 mentions for Altimmune. Immunome's average media sentiment score of 0.93 beat Altimmune's score of 0.56 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunome has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

Summary

Immunome and Altimmune tied by winning 8 of the 16 factors compared between the two stocks.

How does Altimmune compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Altimmune (NASDAQ:ALT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Aurinia Pharmaceuticals has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.11	$287.20M	$2.17	7.22
Altimmune	$40K	12,689.17	-$88.09M	-$0.93	N/A

Aurinia Pharmaceuticals presently has a consensus target price of $17.25, suggesting a potential upside of 10.15%. Altimmune has a consensus target price of $16.67, suggesting a potential upside of 538.57%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Altimmune's net margin of -214,860.98%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Altimmune	-214,860.98%	-42.57%	-35.57%

In the previous week, Aurinia Pharmaceuticals had 3 more articles in the media than Altimmune. MarketBeat recorded 9 mentions for Aurinia Pharmaceuticals and 6 mentions for Altimmune. Aurinia Pharmaceuticals' average media sentiment score of 0.95 beat Altimmune's score of 0.56 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Aurinia Pharmaceuticals beats Altimmune on 11 of the 16 factors compared between the two stocks.

How does Altimmune compare to Pharvaris?

Altimmune (NASDAQ:ALT) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

78.1% of Altimmune shares are owned by institutional investors. 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Altimmune currently has a consensus target price of $16.67, indicating a potential upside of 538.57%. Pharvaris has a consensus target price of $49.18, indicating a potential upside of 56.08%. Given Altimmune's higher probable upside, equities research analysts clearly believe Altimmune is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Pharvaris has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Pharvaris	N/A	-67.56%	-61.13%

Altimmune has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	12,689.17	-$88.09M	-$0.93	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

Altimmune has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.35, suggesting that its share price is 335% less volatile than the broader market.

In the previous week, Altimmune had 2 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for Altimmune and 4 mentions for Pharvaris. Altimmune's average media sentiment score of 0.56 beat Pharvaris' score of 0.43 indicating that Altimmune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Altimmune beats Pharvaris on 12 of the 15 factors compared between the two stocks.

How does Altimmune compare to Bausch Health Cos?

Altimmune (NASDAQ:ALT) and Bausch Health Cos (NYSE:BHC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Bausch Health Cos has a net margin of -11.47% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

In the previous week, Altimmune had 5 more articles in the media than Bausch Health Cos. MarketBeat recorded 6 mentions for Altimmune and 1 mentions for Bausch Health Cos. Altimmune's average media sentiment score of 0.56 beat Bausch Health Cos' score of 0.49 indicating that Altimmune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.1% of Altimmune shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 1.6% of Altimmune shares are held by insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Altimmune presently has a consensus price target of $16.67, suggesting a potential upside of 538.57%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 55.49%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Altimmune has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Bausch Health Cos has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	12,689.17	-$88.09M	-$0.93	N/A
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A

Summary

Altimmune and Bausch Health Cos tied by winning 8 of the 16 factors compared between the two stocks.

How does Altimmune compare to Mineralys Therapeutics?

Altimmune (NASDAQ:ALT) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, Altimmune had 1 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 6 mentions for Altimmune and 5 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.59 beat Altimmune's score of 0.56 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Altimmune has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

Altimmune has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	12,689.17	-$88.09M	-$0.93	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

Altimmune presently has a consensus price target of $16.67, suggesting a potential upside of 538.57%. Mineralys Therapeutics has a consensus price target of $49.33, suggesting a potential upside of 107.63%. Given Altimmune's higher possible upside, analysts plainly believe Altimmune is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Mineralys Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Mineralys Therapeutics' return on equity of -27.92% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 1.6% of Altimmune shares are owned by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Mineralys Therapeutics beats Altimmune on 8 of the 15 factors compared between the two stocks.

Get Altimmune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALT vs. The Competition

Export

Metric	Altimmune	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$507.57M	$2.94B	$6.41B	$11.71B
Dividend Yield	N/A	1.71%	2.67%	5.55%
P/E Ratio	-2.81	17.80	24.46	23.62
Price / Sales	12,689.17	289.23	500.50	105.26
Price / Cash	N/A	55.74	42.36	56.09
Price / Book	1.31	3.88	10.43	6.70
Net Income	-$88.09M	$75.85M	$3.56B	$337.26M
7 Day Performance	-8.90%	-1.87%	-1.39%	-1.41%
1 Month Performance	-15.53%	-6.20%	0.86%	1.15%
1 Year Performance	-61.28%	12.60%	19.42%	22.61%

Altimmune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALT Altimmune	2.0311 of 5 stars	$2.61 -1.9%	$16.67 +538.6%	-55.3%	$507.57M	$40K	N/A	50	News Coverage
IMNM Immunome	3.5998 of 5 stars	$18.61 +0.2%	$33.17 +78.2%	+98.4%	$2.10B	$6.94M	N/A	40	Insider Trade
AUPH Aurinia Pharmaceuticals	3.0196 of 5 stars	$15.66 -1.1%	$17.25 +10.2%	+93.9%	$2.04B	$283.05M	7.22	300	Positive News
PHVS Pharvaris	3.3301 of 5 stars	$31.59 +1.6%	$49.18 +55.7%	+75.3%	$2.03B	N/A	N/A	30	Gap Down
BHC Bausch Health Cos	2.587 of 5 stars	$5.13 -4.6%	$8.00 +56.1%	+6.0%	$2.01B	$10.27B	N/A	20,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALT) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Altimmune (ALT) Competitors

ALT vs. IMNM, AUPH, PHVS, BHC, and MLYS

How does Altimmune compare to Immunome?

Summary

How does Altimmune compare to Aurinia Pharmaceuticals?

Summary

How does Altimmune compare to Pharvaris?

Summary

How does Altimmune compare to Bausch Health Cos?

Summary

How does Altimmune compare to Mineralys Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALT vs. The Competition

Altimmune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Altimmune (ALT) Competitors

ALT vs. IMNM, AUPH, PHVS, BHC, and MLYS

How does Altimmune compare to Immunome?

Is IMNM or ALT more profitable?

Which has higher earnings & valuation, IMNM or ALT?

Do institutionals and insiders hold more shares of IMNM or ALT?

Do analysts rate IMNM or ALT?

Does the media favor IMNM or ALT?

Which has more volatility & risk, IMNM or ALT?

Summary

How does Altimmune compare to Aurinia Pharmaceuticals?

Which has preferable valuation & earnings, AUPH or ALT?

Do analysts rate AUPH or ALT?

Is AUPH or ALT more profitable?

Does the media refer more to AUPH or ALT?

Which has more risk and volatility, AUPH or ALT?

Do institutionals & insiders believe in AUPH or ALT?

Summary

How does Altimmune compare to Pharvaris?

Do institutionals and insiders have more ownership in ALT or PHVS?

Do analysts recommend ALT or PHVS?

Is ALT or PHVS more profitable?

Which has better valuation and earnings, ALT or PHVS?

Which has more risk and volatility, ALT or PHVS?

Does the media prefer ALT or PHVS?

Summary

How does Altimmune compare to Bausch Health Cos?

Is ALT or BHC more profitable?

Does the media prefer ALT or BHC?

Do insiders and institutionals hold more shares of ALT or BHC?

Do analysts prefer ALT or BHC?

Which has more risk and volatility, ALT or BHC?

Which has better earnings and valuation, ALT or BHC?

Summary

How does Altimmune compare to Mineralys Therapeutics?

Does the media prefer ALT or MLYS?

Which has more volatility and risk, ALT or MLYS?

Which has preferable earnings and valuation, ALT or MLYS?

Do analysts prefer ALT or MLYS?

Is ALT or MLYS more profitable?

Do insiders and institutionals hold more shares of ALT or MLYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALT vs. The Competition

Altimmune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools